Skip to main content
Testing version — LOERadar is in active testing. Features and data may change.
LOERadar
LOE
Radar
Intelligence Hub
News
Changes
Search
Log in
Get Started
BAXFENDY (BAXDROSTAT) | LOERadar
Viewing data from:
Latest
2026-07-01
2026-06-01
2026-05-01
2026-04-01
2026-03-28
2026-02-17
2026-02-10
2025-12-14
2025-02-26
2025-01-25
2024-11-08
2023-07-23
2023-06-15
2023-05-13
2023-01-26
2022-11-22
2022-10-28
2022-09-29
2022-07-09
2022-06-29
2022-04-08
2022-03-09
2021-12-28
2021-05-05
2021-03-12
2020-12-22
2020-11-12
2019-12-14
2019-09-15
BAXFENDY
NDA
BAXDROSTAT | N219878 | ASTRAZENECA AB
2 strengths
1 unique patent
1 unique exclusivity
Patents
SEC Intel
Revenue
PTAB
Reexams
Litigation
Petitions
Trials
Approvals
Label
Products
Patent Timeline
1 unique patent, 1 exclusivity by expiration date
All strengths
1MG
2MG
Active (1)
Today
Exclusivity
2027
2028
2029
2030
2031
2032
2033
Today
9353081
Feb. 4, 2033
NCE
May. 15, 2031
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (2)
Sort:
Name
↑
Applicant
Strength
Approval
#001 — 1MG
RLD
1 patent
1 exclusivity
▴
TABLET;ORAL | Approved: May 15, 2026
Patents (1)
Patent #
Expiration
PED
Drug Substance
Drug Product
Use Code
Delist
9353081
Feb 4, 2033
—
Yes
Yes
—
—
Exclusivities (1)
Code
Date
Status
NCE
May 15, 2031
Active
#002 — 2MG
RLD
1 patent
1 exclusivity
▾
TABLET;ORAL | Approved: May 15, 2026